Generics Primed To Fight FDA On Labeling Flexibility
News | 13 February 2013
Law360, New York (February 12, 2013, 8:40 PM ET) -- The U.S. Food and Drug Administration is considering making generic-drug makers responsible for the warnings on their product labels, but attorneys say the industry may attempt to avoid liability by ...
Click on the link to read the full article at Law360 (subscription)
(This link will open in a new window)
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
